PHVS
NASDAQ HealthcarePharvaris N.V. - Ordinary Shares
Biotechnology
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
�� 市场数据
| 价格 | $28.58 |
|---|---|
| 成交量 | 148,412 |
| 市值 | 1.87B |
| 贝塔系数 | -2.580 |
| RSI（14日） | 57.6 |
| 200日均线 | $24.56 |
| 50日均线 | $27.18 |
| 52周最高 | $29.89 |
| 52周最低 | $13.81 |
| Forward P/E | -9.08 |
| Price / Book | 5.84 |
🎯 投资策略评分
PHVS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (58/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PHVS in your text
粘贴任何文章、记录或帖子 — 工具将提取 PHVS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.